Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.48 |
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NQO1 | P15559 | 3/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1648320 | 0.84 | ADORA3 (0.70) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL1647638 | 0.81 | CYP2C9 (0.72) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL1647664 | 0.80 | NQO1 (0.65) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL3157772 | 0.78 | CYP2C9 (0.60) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL1648307 | 0.78 | ADORA3 (0.55) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL5149511 | 0.77 | CYP2C9 (0.50) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL5103750 | 0.74 | CYP2C9 (0.66) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL5972176 | 0.73 | CYP2C9 (0.69) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL5113240 | 0.73 | CYP2C9 (0.69) | ADORA3CYP2C9VKORC1ALBHSD17B10 | |
| SCHEMBL1649881 | 0.73 | ADORA3 (0.65) | ADORA3CYP2C9VKORC1ALBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285671-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2007-10-23 | — | — | US | disclosed |
| US-7253208-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060287388-A1 | Materials and Methods for Treating Coagulation Disorders | ARYX THERAPEUTICS (US) | 2006-12-21 | — | — | US | disclosed |
| US-20050245603-A1 | Materials and methods for treating coagulation disorders | ESPERO BIOPHARMA, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245603-A1 | Materials and methods for treating coagulation disorders | F12, F2, SERPINC1 | ADORA3 124/4885CYP2C9 553/4885VKORC1 38/4885 |
| US-20060287388-A1 | Materials and Methods for Treating Coagulation Disorders | F12, F2, SERPINC1 | ADORA3 124/4885CYP2C9 553/4885VKORC1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.